Apeiron

This page shows the latest Apeiron news and features for those working in and with pharma, biotech and healthcare.

Keytruda and Opdivo backed for new uses in Europe

Apeiron Biologics also got the go-ahead for Dinutuximab beta as a treatment for high-risk neuroblastoma, an orphan indication.

Sanofi and Novartis snap up immuno-oncology candidates

BioNtech - signed last year alongside smaller deals with Selecta, Evotec and Apeiron Biologics.
Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies
Sanofi and Evotec to work together on diabetes and cancer

Meanwhile, the two companies have also agreed to work together with Apeiron Biologics on novel, small-molecule immuno-oncology therapies. ... Sanofi will support two years of research funding for Evotec and Apeiron and could potentially yield more than
Advancing acquisitions

SPA/P2 (as combination). 350. Apeiron Biologics AG/GSK. APN01 - recombinant human angiotensin converting enzyme 2 (rhACE2) in ARDS.
GSK enters licensing deal for ARDS enzyme

GSK enters licensing deal for ARDS enzyme. Apeiron has granted GSK exclusive rights to its APN01 enzyme, in phase I development to treat Acute Respiratory Distress Syndrome. ... The deal will see GSK pay Apeiron an up-front payment of £11m cash and

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Pharma deals in August 2015

Immunology deals. In addition to this and in keeping with the industry fashion, Sanofi has ventured into immuno-oncology with Evotec / Apeiron Biologics. ... As a strategic collaboration it is fairly risk sparing and accesses Apeiron's immunological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

BMS appoints CCO, Stephen Davies joins Eisai and more

Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... major near-term milestones of clinical-stage assets and support the expansion and
Apeiron bolsters management board

Apeiron bolsters management board. Peter Llewellyn-Davies joins as its CFO and CBO. ... Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Add my company

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI...

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...